200 related articles for article (PubMed ID: 24751157)
21. Development of peptide epoxyketones as selective immunoproteasome inhibitors.
Li X; Hong D; Zhang M; Xu L; Zhou Y; Li J; Liu T
Eur J Med Chem; 2021 Oct; 221():113556. PubMed ID: 34087498
[TBL] [Abstract][Full Text] [Related]
22. Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors.
Zhuang R; Gao L; Lv X; Xi J; Sheng L; Zhao Y; He R; Hu X; Shao Y; Pan X; Liu S; Huang W; Zhou Y; Li J; Zhang J
Eur J Med Chem; 2017 Jan; 126():1056-1070. PubMed ID: 28027531
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, biological evaluation, and structure-activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: comprehensive understanding of the SAR of alpha-amino acid boronates.
Zhu Y; Zhao X; Zhu X; Wu G; Li Y; Ma Y; Yuan Y; Yang J; Hu Y; Ai L; Gao Q
J Med Chem; 2009 Jul; 52(14):4192-9. PubMed ID: 19537716
[TBL] [Abstract][Full Text] [Related]
24. Immunoproteasome β5i-Selective Dipeptidomimetic Inhibitors.
Singh PK; Fan H; Jiang X; Shi L; Nathan CF; Lin G
ChemMedChem; 2016 Oct; 11(19):2127-2131. PubMed ID: 27561172
[TBL] [Abstract][Full Text] [Related]
25. Activity enhancement of the synthetic syrbactin proteasome inhibitor hybrid and biological evaluation in tumor cells.
Archer CR; Groll M; Stein ML; Schellenberg B; Clerc J; Kaiser M; Kondratyuk TP; Pezzuto JM; Dudler R; Bachmann AS
Biochemistry; 2012 Aug; 51(34):6880-8. PubMed ID: 22870914
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological properties of C-terminal vinyl ketone pseudotripeptides.
Franceschini C; Trapella C; Sforza F; Gavioli R; Marastoni M
J Enzyme Inhib Med Chem; 2013 Jun; 28(3):560-4. PubMed ID: 22380778
[TBL] [Abstract][Full Text] [Related]
27. Enzyme inhibition by hydroamination: design and mechanism of a hybrid carmaphycin-syringolin enone proteasome inhibitor.
Trivella DB; Pereira AR; Stein ML; Kasai Y; Byrum T; Valeriote FA; Tantillo DJ; Groll M; Gerwick WH; Moore BS
Chem Biol; 2014 Jun; 21(6):782-91. PubMed ID: 24930969
[TBL] [Abstract][Full Text] [Related]
28. Design and discovery of novel dipeptide boronic acid ester proteasome inhibitors, an oral slowly-released prodrug for the treatment of multiple myeloma.
Wang X; Zhang W; Wen T; Miao H; Hu W; Liu H; Lei M; Zhu Y
Eur J Med Chem; 2023 Mar; 250():115187. PubMed ID: 36806958
[TBL] [Abstract][Full Text] [Related]
29. Exploration of novel four-membered-heterocycle constructed peptidyl proteasome inhibitors with improved metabolic stability for cancer treatment.
Wang H; Wu Z; Cao Y; Gao L; Shao J; Zhao Y; Zhang J; Zhou Y; Wei G; Li J; Zhu H
Bioorg Chem; 2023 Sep; 138():106626. PubMed ID: 37295239
[TBL] [Abstract][Full Text] [Related]
30. Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma MM.1R cells.
Ettari R; Pallio G; Pizzino G; Irrera N; Zappalà M; Maiorana S; Di Chio C; Altavilla D; Squadrito F; Bitto A
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1307-1313. PubMed ID: 31307247
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine.
Jorda R; Dušek J; Řezníčková E; Pauk K; Magar PP; Imramovský A; Kryštof V
Eur J Med Chem; 2017 Jul; 135():142-158. PubMed ID: 28441582
[TBL] [Abstract][Full Text] [Related]
32. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
[TBL] [Abstract][Full Text] [Related]
33. Terminal functionalized thiourea-containing dipeptides as multidrug-resistance reversers that target 20S proteasome and cell proliferation.
Qin JM; Huang RZ; Yao GY; Liao ZX; Pan YM; Wang HS
Eur J Med Chem; 2017 Jan; 126():259-269. PubMed ID: 27889629
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and activity of tyropeptin A derivatives as potent and selective inhibitors of mammalian 20S proteasome.
Momose I; Umezawa Y; Hirosawa S; Iijima M; Iinuma H; Ikeda D
Biosci Biotechnol Biochem; 2005 Sep; 69(9):1733-42. PubMed ID: 16195592
[TBL] [Abstract][Full Text] [Related]
35. Discovery and development of second-generation proteasome inhibitors.
Kirk CJ
Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
[TBL] [Abstract][Full Text] [Related]
36. Potent proteasome inhibitors derived from the unnatural cis-cyclopropane isomer of Belactosin A: synthesis, biological activity, and mode of action.
Kawamura S; Unno Y; List A; Mizuno A; Tanaka M; Sasaki T; Arisawa M; Asai A; Groll M; Shuto S
J Med Chem; 2013 May; 56(9):3689-700. PubMed ID: 23547757
[TBL] [Abstract][Full Text] [Related]
37. Proteasome inhibitors: introduction.
Heuck CJ; Shaughnessy JD
Semin Hematol; 2012 Jul; 49(3):193-5. PubMed ID: 22726541
[No Abstract] [Full Text] [Related]
38. Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
Dong XW; Zhang JK; Xu L; Che JX; Cheng G; Hu XB; Sheng L; Gao AH; Li J; Liu T; Hu YZ; Zhou YB
Eur J Med Chem; 2019 Feb; 164():602-614. PubMed ID: 30639896
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
Zhang J; Shen L; Wang J; Luo P; Hu Y
Med Chem; 2014; 10(1):38-45. PubMed ID: 23676009
[TBL] [Abstract][Full Text] [Related]
40. Tyropeptins, proteasome inhibitors produced by Kitasatospora sp. MK993-dF2.
Momose I; Watanabe T
J Antibiot (Tokyo); 2017 May; 70(5):542-550. PubMed ID: 28196975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
